Evidence map›Paper›PMID 35632708›Full record

ArticleViruses2022

C57BL/6J Mice Are Not Suitable for Modeling Severe SARS-CoV-2 Beta and Gamma Variant Infection.

Joshua M Currey, Felix Rabito, Nicholas J Maness, Robert V Blair, Jay Rappaport, Xuebin Qin, Jay K Kolls, Akhilesh K Srivastava

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Upregulation of inflammatory genes and pathways links obesity to severe COVID-19.Biochimica et biophysica acta. Molecular basis of disease · 2024
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Joshua M CurreyTulane National Primate Research Center, Covington, LA 70433, USA.
Felix RabitoCenter for Translational Research in Infection and Inflammation, John W. Deming Department of Medicine, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Nicholas J ManessTulane National Primate Research Center, Covington, LA 70433, USA.ORCID 0000-0002-9332-7891
Robert V BlairTulane National Primate Research Center, Covington, LA 70433, USA.
Jay RappaportTulane National Primate Research Center, Covington, LA 70433, USA.
Xuebin QinTulane National Primate Research Center, Covington, LA 70433, USA.
Jay K KollsCenter for Translational Research in Infection and Inflammation, John W. Deming Department of Medicine, Tulane University School of Medicine, New Orleans, LA 70112, USA.ORCID 0000-0001-5151-6304
Akhilesh K SrivastavaCenter for Translational Research in Infection and Inflammation, John W. Deming Department of Medicine, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Tulane University · US

Funding

Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4M
Tulane University COVID Antibody and Immunity Network (TUCAIN) SupplementU54CA260581 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI ROBINSON, JAMES E · 2020 to 2024
$9.2M
Training in CD4 T-cell Lung ImmunityR35HL139930 · NHLBI · TULANE UNIVERSITY OF LOUISIANA · PI KOLLS, JAY K · 2018 to 2024
$6.3M
Role of Complement Activation in Severe COVID-19R01HL165265 · NHLBI · TULANE UNIVERSITY OF LOUISIANA · PI QIN, XUEBIN · 2022 to 2025
$2.9M
Generation and Characterization of a Novel Cell Subpopulation Ablation ModelR21OD024931 · OD · TULANE UNIVERSITY OF LOUISIANA · PI QIN, XUEBIN · 2018 to 2019
$450k
Abrogating human CD59 activity for antibody-based cancer therapyR21CA141324 · NCI · HARVARD MEDICAL SCHOOL · PI QIN, XUEBIN · 2010 to 2011
$399k
American Heart Association-American Stroke Association 962950NCI NIH HHS R21 CA141324NCI NIH HHS U54 CA260581NHLBI NIH HHS R35 HL139930NIH HHS P51 OD011104NIH HHS R21 OD024931
6 · The paper itself

Abstract

SARS-CoV-2 variants, including B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta) variants, have displayed increased transmissibility and, therefore, have been categorized as variants of concern (VOCs). The pervasiveness of VOCs suggests a high probability of future mutations that may lead to increased virulence. Prior reports have shown that VOC infection without expression of human angiotensin converting enzyme-2 receptor (hACE2) in mice is possible. We sought to understand if the increased transmissibility of VOCs can infect C57BL/6 mice without expression of hACE2 receptor required for entry of SARS-CoV-2 normally. We examined the ability of infection with Beta and Gamma variants to infect and cause both pathological and clinical changes consistent with severe COVID-19, including body weight changes, survival, subgenomic viral titer, lung histology on Hematoxylin and Eosin (H&E) staining, and viral protein expression as measured by immunohistochemistry staining of viral antigen (IHC). These methods were used to examine three groups of mice: C57BL6,

Indexed as

COVID-19Disease Models, AnimalSARS-CoV-2Angiotensin-Converting Enzyme 2AnimalsHumansMiceMice, Inbred C57BLMice, KnockoutViral ProteinsACE2 protein, humanAngiotensin-Converting Enzyme 2Viral Proteinsimmunocompromised miceSARS-CoV-2variants of concern

Identifiers

PMID35632708
PMCPMC9145451
OpenAlexW4229067811

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.